Serif Biomedicines

Executive Summary

Serif Biomedicines is a private, early-stage biotechnology company headquartered in Cambridge, MA, founded in 2021. The company is pioneering a novel platform for genetic medicines that programs the behavior of nucleic acids in vivo, combining insights from RNA therapeutics and small molecules. Its approach aims to address previously undruggable targets by precisely controlling nucleic acid function. While specific pipeline programs remain undisclosed, the platform has broad potential in treating and preventing diseases. As a privately held company with limited public information, Serif is likely in preclinical development and has not yet announced significant milestones. The biotech sector's competitive landscape and the inherent risk of early-stage platform companies contribute to a highly uncertain outlook.

Upcoming Catalysts (preview)

• Q2 2026Series A Financing50% success